ASX Stocks on the Decline: Which Ones Are Losing Investor Trust?

Three ASX companies are losing investor confidence which leads to sharp decline in their share prices. This blog examines the key concerns and developments behind the market sell-off.

Kogan.com Limited (ASX: KGN)

On 24 August 2026, announced its full year results for FY26 which reflects strong performance as the group gross sales exceeded $1 billion with a growth of around 12% but the revenue only increased by 5% to $510.7.

Kogan.com performed relatively well, offsetting a poorer performance by Mighty Ape as its revenue declined by 30% to $85.6 million with a 23% fall in gross margin.

The company has a market capitalisation of approximately $427.52 million with a dividend yield of 3.32% and has also announced a dividend of 8cps to be paid on 30 November 2026.

KGN’s guidance remains modest with a relatively poor performance of Mighty Ape for July 2026, which seems to justify the negative investor sentiments despite strong overall growth in the company.

Microba Life Sciences Limited (ASX: MAP)

On  16 July 2026, released its quarterly results showing strong growth as its core testing revenue rose by around 92% with an increment in testing volumes by around 78% during the year. But the company still remains loss making and faces significant cash requirements.

The company has a market cap of around $40.87 million and is heavily relied on external funding for its development. It has raised around $5 million in June through share placement also.

While the SYNLAB agreement provides multi-year opportunity, the investors still remains cautious about its execution and cash burn.

The significant decline in share price reflects declining investor confidence as strong growth in revenue is yet to reflect positive earnings and cash flows.

Rubicon Water Limited (ASX: RWL)

On 24 August 2026, announced its full year results for FY26, showcasing a poorer performance as the revenue went down by 12% to $61.1 million and operating expenses also increased which created a great impact as the losses more than doubled compared to previous year.

The company has a market capitalisation of around $48.15 million and has stated 4 reasons justifying the slower growth which includes delays in US federal funding, the timing of contract finalisation in Asia and Europe, the Middle East, and Africa (EMEA), and the impact of a stronger Australian dollar, together with a non-cash partial derecognition of deferred tax assets.

The poor performance was heavily reflected in the markets as the price fell drastically post results announcements, highlighting a loss in investor confidence.

The company has also provided the guidance for the current year stating to focus on the existing projects while continuing to build the base business, and progressing corporate and basin-scale opportunities.

(Source: Company Announcements)